CORE is a phase 3 multicenter, randomized, double-blind, placebo-controlled trial of ~540 patients to evaluate the safety and efficacy of ISIS 678354, an antisense oligonucleotide inhibitor of apoC-III production, administered subcutaneously to patients with severe hypertriglyceridemia.
MAIN RESULTS:
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
N Engl J Med. 2026 Jan 29;394(5):429-441.
PRIMARY RESULTS PRESENTATION
OTHER PRESENTATIONS
Olezarsen for Acute Pancreatitis Risk in Patients with Triglycerides Greater Than or Equal To 10 mmol per Liter (Zimerman, EAS 2026)
ApoC3 Inhibitor Olezarsen Markedly Reduces Triglycerides & Risk of Pancreatitis in Severe Hypertriglyceridemia Patients with Diabetes Mellitus-Insights from CORE-TIMI 72a and CORE2-TIMI 72b (Kang, ADA 2026)
Prevention of Acute Pancreatitis With APOC3 Inhibition in Severe Hypertriglyceridemia Across Triglyceride Levels and Prior Pancreatitis (Moura, ENDO 2026)
Apolipoprotein C-III (APOC3) Inhibition For Severe Hypertriglyceridemia in Patients With Versus Without Baseline Fibrate Use (Wang, ENDO 2026)
Olezarsen in Patients with Severe Hypertriglyceridemia (Marston, NLA 2026)
PUBLICATIONS
CORE on ClinicalTrials.gov
Contact Us about CORE